Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin.
A 32-year-old woman with human immunodeficiency virus (HIV) infection and progressive anemia presented to University Hospital with a hemoglobin of 3.4 g/dl. Because of her religious beliefs, she refused transfusion, and no iron or vitamin deficiency was found. She responded to recombinant human erythropoietin 150 U/kg intramuscularly thrice weekly with a rise in hemoglobin to 9.3 g/dl by 3 months of treatment. The serum erythropoietin level before treatment was markedly elevated at 1,340 mU/ml.
DaCosta
N A
NA
Department of Medicine, State University of New York, Stony Brook.
Hultin
M B
MB
D000328:Adult; D000740:Anemia / Q000097:blood / Q000150:complications* / Q000628:therapy; D004921:Erythropoietin / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin